Document:

EX-10.28

 Exhibit 10.28 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. 
 EXCLUSIVE LICENSE AGREEMENT 

AMENDED AND RESTATED 

This Agreement, originally effective as of July 28, 2004, and as amended and restated December 16, 2011, is by and between the
institute for Research in Biomedicine (“IRB”), with an address at Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland and Humabs Holding GmbH, with an address at c/o Risk-Consult AG, Poststrasse 22,
6300 Zug, Switzerland (“Humabs” or “Licensee”). 
 WHEREAS, the IRB and Humabs have entered into an exclusive license
agreement dated July 28, 2004 related to the IRB’s proprietary technologies for human monoclonal antibodies; and 
 WHEREAS, the
IRB and Humabs desire to amend and restate such agreement as hereinafter set forth to, among other things (i) provide for royalties on commercial human monoclonal antibody products developed with the IRB using the Platform Technology (as
defined below), and (ii) to clarify that human monoclonal antibody technologies of the IRB and resulting antibodies developed before the effective date of this Agreement or developed in the US fall within the terms of this License Agreement
without further action of the parties in accordance with the terms and conditions of this Agreement; 
 WHEREAS, on the date hereof Humabs
and Humabs Biomed SA, a Swiss wholly owned subsidiary of Humabs (“Humabs Biomed”) have entered into a license agreement sublicensing to Humabs Biomed the Licensed 1P (with retained rights for certain sublicenses previously granted by
Humabs) for the development of antibodies in Humabs Biomed’s facility in Switzerland and concurrently Humabs Biomed has entered into a license agreement with IRB relating to development of antibodies by Humabs Biomed in collaboration with IRB
(the “Swiss License Agreement”); 
 Therefore, the IRB and Humabs agree as follows: 

1. DEFINITIONS. 

“Affiliate” means any legal entity (such as a corporation, partnership, or limited liability company) that controls, is controlled
by, or under common control with another legal entity, whether by contract, ownership of assets, voting securities or otherwise. 

“Licensed Antibodies” means the antibodies developed using the Platform Technology which are set forth on Exhibit A to this
Agreement 
 “IRB Know-How” means [***] to the extent such is not included in the Patent
Rights. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 

 “Know-How Rate” means a royalty rate that
is [***] of the royalty rate that would payable on Licensed Products covered by Valid Claims. 
 “Licensed Products” means any
drug, vaccine or diagnostic product containing Licensed Antibodies. 
 “Licensed JP” means intellectual property comprising the
Patent Rights and the IRB Know-How. 
 “Patent Rights” means all unexpired and unabandoned patents and patent applications owned
by the IRB covering the Platform Technology and the Licensed Antibodies set forth in the patents and patent applications listed on Exhibit A, and all continuations,
continuations-in-part, divisionals, reissues, reexaminations and the like, whether existing as of the date hereof or later developed. 

“Sublicense Income” means [***] granted Humabs under Section 2.1. 

“Sublicensee” means any non-Affiliate sublicensee of the rights in Licensed Antibodies
granted Humabs under this Agreement. 
 “Platform Technology” means the technology associated with [***] owned by the IRB. 

“Term” means, unless earlier terminated in accordance with the provisions of this Agreement, the term of this Agreement, which
shall remain in effect until the expiration or abandonment of all Valid Claims of the Patent Rights and trade secrets embodied in the IRB Know-How. 

“Valid Claim” means for any country, a claim of an issued and unexpired patent or application included in the Patent Rights
that would be infringed by the exploitation of the Platform Technology or a product derived therefrom but for the license granted herein and has not been abandoned or cancelled or found by a court to be, or admitted to be, invalid or
unenforceable. 
 2. LICENSE GRANT. 

2.1 License Grant. Subject to the terms of this Agreement, the IRB grants to Humabs an exclusive (even as to the IRB and its Affiliates)
world-wide royalty-bearing License to the Licensed IP for any and all purposes, including without limitation to practice the Platform Technology, and to make, have made, use, sell, offer to sell, lease, import, export, distribute, modify and
otherwise exploit Licensed Products. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 2 

 2.2 Sublicenses. Humabs shall have the right to grant sublicenses under this Agreement
including sublicenses through multiple levels of sublicensees. Humabs shall incorporate terms and conditions into its sublicense agreements sufficient to enable Humabs to comply with its obligations under this Agreement. Humabs shall
immediately inform IRB of the execution of any sublicense agreement and make available to IRB within [***] from the execution of each sublicense agreement a copy of the same. 

2.3 Retained Rights. The IRB retains the right to practice the Licensed IP solely for internal research, teaching, and educational purposes, but not for
any commercial exploitation. Such retained rights shall be non-exclusive, non-transferable, and non-sublicensable.
Notwithstanding the foregoing, the IRB may [***]. The IRB may not [***]. For the avoidance of doubt the parties acknowledge that any practicing of the Licensed IP by IRB with the purpose to [***]. 

2.4 [***] License Agreement. The IRB and Humabs, LLC are parties to an Exclusive License Agreement (the “[***] License”) dated as of
May 30, 2008, in respect of Antibodies [***] (as defined therein). Such Antibodies [***] shall not be subject to this Agreement, but shall be governed by the terms of the [***] License. 

3. DUE DILIGENCE. 
 3.1 Diligence
Requirements. Humabs shall use commercially reasonable efforts to develop and commercialize Licensed Products and shall at all times maintain an active program (whether directly or through sublicensees) to commercialize Licensed Products. [***].
Humabs undertakes to deliver IRB at least at the end of January and July of each year a [***] during the preceding calendar semester (i.e. during the period July-December and January-June) and the actions planned for the next calendar semester. 

4. LICENSE PAYMENTS.  
 4.1 [***] 

4.2 Royalties. 
 a. Running Royalties on
Sales by Humabs of Licensed Products. Humabs shall pay to the 1RB a royalty in respect of Net Sales (as defined below) of Licensed Products covered by Valid Claims (on a
country-by-country basis) of [***], and [***]. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 3 

 b. Net Sales. “Net Sales” means the gross amount [***], less Permitted
Deductions. “Permitted Deductions” means the following amounts incurred by [***] any Licensed Product. Net Sales shall be deemed to occur on the date of receipt of payment. 

c. Sublicense Income. Humabs shall pay to the IRB a royalty (“Sublicense Royalty”) equal to [10%] of Sublicense Income
received by Humabs and its Affiliates from Sublicensees in respect of such sublicense. Any payments under this section 4.2(c) will be [***] for the first such milestone/upfront payment received by Humabs, and at [***] received by Humabs in respect
of such Licensed Product. In order to illustrate the foregoing, if Humabs entered into a Sublicense agreement providing for an initial upfront payment for a Licensed Product of $12 million followed by milestone payments of $10 million and
$ l2 million, Humabs would [***]. 
 d. Know-How Rate. Any royalty otherwise due
under this Section 4.2 for a Licensed Product covered by a Valid Claim shall be reduced to the Know-How Rate in the event that such Licensed Product is :not covered on a country-by-country basis, by a Valid Claim. No royalties shall be payable under IRB Know-How for any Licensed Product in any country after ten years from the date of
first commercialization of such Licensed Product in that country. 
 e. Royalty Stacking. If on a country-by-country basis Humabs must pay a third party to license or otherwise acquire rights to any [***], then Humabs shall be entitled to deduct [***], provided that the royalty paid to the IRB shall in no
event be less than [***] of the royally that would have been paid in the absence of the adjustment provided by this section 4.2(d). In order to avoid doubt no royalty reduction shall be made pursuant to this section 4.2(d) in respect of payments to
[***]. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 4 

 4.3 Payment Terms.  

a. Payments in U.S. Dollars. Royalties shall be payable in arrears for each calendar quarter and shall be due to the IRB within [***] of
the end of each such quarter. All payments due under this Agreement shall be drawn on a United States bank and shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion
rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of the applicable Reporting Period. 

b. Foreign Restrictions. If at any time legal restrictions in any country prevent the prompt remittance of any payments to the IRB from
revenues earned in that country Humabs shall have the option to make such payments by depositing the amount thereof in local currency to IRB’s account in a bank or depository in such country. 

c. Taxes. The IRB will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are
required to be withheld by Humabs Humabs will: (a) deduct such taxes from the payment made to the IRB; (b) timely pay the taxes to the proper taxing authority; (c) send proof of payment to the IRB; and (d) reasonably assist the
IRB in its efforts to obtain a credit for such tax payment. Each Party agrees to reasonably assist the other Party in lawfully claiming exemptions from and/or minimizing such deductions or withholdings under double taxation laws or similar
circumstances. 
 5. DISCLOSURE, REPORTS AND CONFIDENTIALITY. 

5.1 Disclosures and Technology Transfer. The parties will promptly disclose to each other any inventions made relating to this Agreement. The IRB will
transfer to Humabs [***]. 
 5.2 Reporting Requirements. 

a. Humabs. In connection with [***]. Such reports shall in no case be issued less than biannually. 

b. IRB. IRB will keep Humabs informed of [***]. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 5 

 5.3 Royalty Reporting and Audits. 

a. Licensee shall keep, and shall require its Affiliates and Sublicensees to keep, complete and accurate records of their sales of Licensed
Products in sufficient detail to allow the accruing Royalties to be determined accurately, and to maintain such records for a minimum of three years following the end of the quarter during which such sales occurred. 

b. IRB shall have the right with respect to Royalties due and payable, to appoint an independent certified public accountant reasonably
acceptable to Licensee to inspect the relevant records of Licensee (and, to the extent applicable, its Affiliates and Sublicensees) as may be reasonably necessary to verify the accuracy of the payment reports hereunder for any year ending not more
than [***] prior to the date of such request. 
 c. Licensee shall promptly make such records available for inspection by such independent
certified public accountant during Licensee’ (or its Affiliate’s or Sublicensee’s, as applicable) regular business hours at such place or places where such records arc customarily kept, upon reasonable notice from IRB, solely to
verify the accuracy of the reports and payments. Such inspection right shall not be exercised more than once in any calendar year. The foregoing inspection right shall survive for a period of [***] after expiration or termination of this Agreement

 d. IRB agrees to hold in confidence all Confidential Information (as defined below) concerning Royalties and reports, and all Confidential
Information learned in the course of any audit or inspection (and not to make copies of such reports and information), except to the extent necessary for IRB to reveal such information in order to enforce its rights under this Agreement or if
disclosure is required by law, regulation or judicial order. The results of each inspection, if any, shall be binding on both parties. 
 e.
IRB shall pay for such inspections set forth herein, except that in the event there is any upward adjustment in aggregate Royalties payable for any year shown by such inspection of more than [***] of the amount paid Licensee shall pay the cost of
such inspection. la the event an inspection conducted pursuant to this Section reveals an underpayment of Royalties due Licensee shall pay the difference [***] of the date IRB delivers to Licensee such accountant’s written report so concluding.
Any overpayments shall be fully creditable against amounts payable in subsequent payment periods. 
 5.4 Confidentiality. During the term of this
Agreement, and for a period of [***] thereafter or for so long as such information is maintained in confidence, if longer, each party hereto will maintain in confidence all information disclosed by the other party hereto (“Confidential
Information”) that is marked, identified as or otherwise reasonably treated by the disclosing party as confidential at the time of disclosure to the other party. The parties acknowledge that the Platform Technology, the IRB Know-How and information concerning Licensed Antibodies or Licensed Products (to the extent not published in patent applications) is confidential. Neither party shall use disclose or grant use of such Confidential
Information except as permitted under this Agreement. Each party shall use commercially reasonable efforts to ensure that its and its Affiliates’ Sublicensees officers, directors, employees, agents and consultants only make use of Confidential
Information for the purpose of this Agreement and do not disclose or make any unauthorized use of such Confidential Information. Each party shall promptly notify the other upon discovery of any unauthorized use or disclosure of Confidential
Information. Confidential Information shall not include any information which and to the extent: 
 i. was already known to the receiving
party, other than under an obligation of confidentiality, at the time of disclosure by the other party; 

  
 /s/WJR /s/SRC /s/JN /s/GN

  
 6 

 ii. was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the other party; 
 iii. becomes generally available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving party in breach of this Agreement· 
 iv. was disclosed to the
receiving party, other than under an obligation of confidentiality, by a third party who had no obligation to the other party not to disclose such information- or 

v. was independently developed by the receiving party without reference to the disclosure by the other party. 

5.5 Terms of the Agreement. Licensee and IRB shall keep the financial terms and specific provisions of this agreement confidential.
However, either party may provide a copy of this agreement to [***]. Furthermore, Licensee and IRB acknowledge that either party may be obligated to disclose the terms of this agreement and make the complete text of this agreement publicly
available in the event required by applicable law or regulation, including without limitation a registration statement with respect to the sale of shares of capital stock is filed, or if Licensee otherwise becomes a public company; in such event,
the financial terms or this agreement shall be redacted in the copy that is made public to the maximum extent that counsel advises is permissible. 

5.6 Permitted Disclosures. Each party may disclose Confidential information to the extent such disclosure is reasonably necessary
in filing or prosecuting patent applications, prosecuting or defending litigation, or complying with any applicable statute or governmental regulation, provided such party has given the disclosing party prompt written notice allowing it
to limit such disclosure. In addition, either party may disclose Confidential Information to its Affiliates and to its Sublicensees; provided, however, in connection with any such disclosure the disclosing party shall secure confidential
treatment of such Confidential Information. 
 5.7 Publication. The IRB shall have the right to publish and/or present information
about the Platform Technology and/or the Licensed Antibodies (each, a “Publication”), subject to the following conditions: (a) IRB will submit all proposed Publications to the Licensee for review in advance of submission to any
publisher or other third party; (b) Licensee shall have [***] from the date it received the proposed Publication to review the proposed Publication; (c) the Licensee shall have the right to [***] and require that any Confidential
Information or Licensee (including trade secrets and patent protected materials) and product information be deleted from the proposed Publication; and (d) the Licensee shall have the right to request a delay in publication of up to [***]

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 7 

 
Publication in order to protect tbc potential patentability of any Licensee information contained therein. In addition, IRB shall [***] acknowledge the contributions and publications of the
Licensee as scientifically appropriate. 
 6. PATENTS. 

6.1 Ownership. To the extent IRB has no original ownership of patents pursuant to the applicable law and/or appropriate contractual arrangements with
its employees ownership of patents will follow inventorship in the first instance, as determined according to US law. Both Humabs and the IRB will require their employees to assign patents to their respective institutions and
otherwise cooperate with patent prosecutions. Joint inventions and inventions developed with the IRB using the Platform Technology with Humabs financial support which comprise Licensed IP will nonetheless be owned by the IRB. The parties shall
execute assignments as necessary to give effect to the foregoing. 
 6.2 Patent Prosecution. [***] shall prepare, file, prosecute and maintain all
patent applications and patents comprising Licensed IP in consultation with [***], in each case using commercially reasonable and diligent efforts and using appropriate counsel of [***] choice. [***] shall bear all costs associated
therewith. [***] shall have the sole right to determine all matters related to its patent filing prosecution and maintenance strategy, in its commercially reasonable discretion. [***] shall cause its employees, agents or consultants, at the
sole expense of [***], to execute such documents and to take such other actions as reasonably necessary or appropriate to comply with its obligations hereunder. In the event that [***] desires not to proceed with the filing, or to cease its
prosecution or maintenance, of any patent application or patent hereunder, [***] shall promptly (and in any event within a timeframe reasonably sufficient to permit [***] to take appropriate action) notify [***], and in such event, or if [***]
otherwise fails to pursue such prosecution or maintenance, [***] shall have the right to continue such prosecution and maintenance in [***] name at [***] cost and expense. Any patents issued as a result thereof will not be added to this
Agreement unless [***] and [***] agree to the contrary in writing in a separate agreement, that shall also govern the terms and conditions of the adding of such patent to this Agreement. The parties acknowledge that nothing in this
Section 6.2 shall be interpreted to the effect of imposing on [***] an obligation to enter into or negotiate such a separate agreement and may license such patent lo a third party licensee. 

6.3 Infringement. Each party shall notify the other party if it becomes aware that a third person is infringing a Patent Right. Licensee will have the
right and obligation to bring an action concerning such infringement in its own name and IRB’s name to the extent that IRB is a necessary party (unless Licensee determines in its reasonable judgment that for strategic or other reasons
it is not advisable to bring such an action). Lf Licensee does not bring such action within [***] after notice from IRB (or earlier time if reasonably necessary under the circumstances), then IRB (without waiving its remedies against Humabs that has
breached its obligation to bring action) will have the right to bring such an action in its own name unless Humabs’ board of directors determines in good faith that such action would result in risks to the Patent Rights which outweigh the
potential benefits of such action. Notwithstanding the foregoing, if either party is required to bring an action in or in conjunction with the other party s name in order to 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 8 

 properly protect the Patent Rights such party may do so and the other party hereby consents to such use of
its name and agrees to cooperate in such action as reasonably requested by the party bringing such action. Absent a later agreement between the parties, (a) [***] or (b) [***]· provided, however, that neither party shall
conduct, settle or compromise such action in any manner that will materially diminish. dilute or impair the other party’s rights under this Agreement or the validity or enforceability of any Patent Right without the prior consent of the
other party, which consent shall not be unreasonably withheld conditioned or delayed. 
 6.4 [***]  

6.5 Sublicensed Licensed Products. If Humabs enters into a commercial sublicense for the development, commercialization and sale of
Licensed Products, the provisions of such sublicense with respect to filing, prosecution, and maintenance of patent rights with respect to such Licensed Products, and infringement of such rights shall govern and any other provisions
of Sections 6.2 and 6.3 shall not apply to such sublicensed Licensed Antibodies. 
 7. BIOLOGICAL MATERIALS. 

7.1 Ownership of Tangible Materials. Humabs will own all tangible materials such as antibodies, cell lines and other biological materials developed by
the parties hereunder. IRB may transmit antibodies to other academic institution in connection wiU1 research collaborations otherwise permitted by this Agreement if it first obtains the consent of Humabs such consent not to be unreasonably withheld.
[***] 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 9 

 8. REPRESENTATIONS AND WARRANTIES 

8.1 Power and Authority. Each party represents and warrants to the other that (a) it has full authority to execute and deliver this Agreement and
lo carry out the transactions contemplated hereby; (b) this Agreement has been duly authorized executed and validly delivered by it and is binding and enforceable against it in accordance with its terms, except as such enforceability
may be limited by applicable insolvency and other laws affecting creditors’ rights generally, or by the availability of equitable remedies· and (c) the execution and delivery of this Agreement by it will not violate any
law, regulation or court order or breach or cause a default under any agreement to which it is a party. 
 8.2 Intellectual Property. IRB represents
and warrants Lo Licensee that (a) the IRB has disclosed to Licensee all Patents owned by the IRB that claim the Platform Technology; (b) it owns all right title and interest in and to the Patent Rights and has all necessary rights to
grant the rights to the Patent Rights as set forth elsewhere in this Agreement, including without limitation from [***]; (c) to the best of its knowledge it owns all right title and interest in and to the
IRB Know-How and has all necessary rights to grant the rights to the IRB Know-How as set forth elsewhere in this Agreement, including without limitation, from
[***]· (d) it has not assigned, transferred, or otherwise encumbered its rights in or to the Licensed IP or agreed to do so (other than the Licenses set forth in this Agreement); (c) it has not licensed to any third party its rights
in or to the Licensed IP Rights or agreed to do so (other than the licenses set forth in this Agreement}, (f) it has received no written notices of any lawsuits or pending lawsuits, or any correspondence from the United States Patent and
Trademark Office or any foreign counterpart, with respect to the patentability or validity of any of the claims of the Patent Rights; (g) it has received no written notices or claims that the practice of the Licensed IP rights violate, infringe
or misappropriate any third party’s intellectual property rights· and (h) any consent approval, or authorization of any third party that is required by IRB in connection with the granting of the license rights herein bas been
obtained. 
 8.3 LIMITATION OF LIABILITY  
 EXCEPT IN
CONNECTION WITH THE INDEMNIFICATION OBLIGATIONS SET FORTH IN ARTICLE 9 BELOW AND EXCEPT IN THE CASES IN WHICH IT IS NOT ALLOWED UNDER THE APPLICABLE LAW TO LIMIT OR EXCLUDE LIABILITY, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INDIRECT,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OF ANY KIND INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST .PROFITS, REGARDLESS OF WHETHER SUCH PARTY SHALL BE ADVISED SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
P0SS1BLLITY OF THE FOREGOING. 
 9. INDEMNIFICATION 

9.1 Indemnity. Licensee hereby agrees to indemnify IRB its Affiliates and their respective directors, trustees, officers and employees (the
“Indemnified Parties”) from and against all damages, settlement amounts costs and expenses (including reasonable attorney’s fees) (collectively “Damages”) that the Indemnified Parties are required to pay to third parties to
the extent such Damages arise out of or relate to (a) the exercise of this license or any sublicense thereto by Licensee its Affiliates or Sublicensees, and (b) Licensee’s breach of any representation, warranty or covenant contained
in this Agreement. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 10 

 9.2 Indemnification Procedures. The Indemnified Party shall give prompt notice to Licensee upon
receipt of any written notice of the commencement of any claim for which the Indemnified Party may claim indemnification pursuant to this Article; provided, however that failure to give such notification shall not affect the indemnification provided
hereunder except to the extent Licensee shall have been actually prejudiced as a result of such failure. The Indemnified Party shall give Licensee authority to defend or settle the claim or action and the indemnified Party shall cooperate fully with
Licensee in connection therewith. The Indemnifying Party shall keep the Indemnified Party informed of the progress of any claim or action that Licensee is defending or attempting to settle. The Indemnified Party (a) will, at the expense of
Licensee, cooperate in all reasonable respects with Licensee in connection with such defense, (b) will not admit any liability with respect to, or settle compromise or discharge any claim without Licensee’s prior written consent, and ( c)
will agree to any settlement compromise or discharge of a claim which Licensee may recommend and which by its terms (i) obligates Licensee to pay the full amount of the liability in connection with such claim; and (ii) includes the
unconditional release of the Indemnified Party from all liability arising from such claim. The Indemnified Party shall be entitled to retain its own counsel al its own expense (unless such counsel is necessary because of a conflict of Licensee of
its counsel, in which case Licensee shall bear such expense) to participate in the defense of the claim. 
 9.3 Insurance. Licensee, at its sole cost
and expense shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance no less than (a) commencing not less than [***]· provided, however, that the coverage and limits
referred to above shall not in any way limit the liability of Licensee and such limits shall be reduced to the extent not available on commercially reasonable terms. Upon IRB’s request, Licensee shall furnish IRB with certificates of
insurance showing compliance with the foregoing. Such certificates shall to the extent commercially reasonably available: (a) provide for [***] advance written notice to IRB of any material modification· (b) indicate that IRB is a named
insured on Licensee’s policy, such that IRB is listed on the declarations page of that policy as a named insured; and (c) include a provision that the coverage shall be primary and shall not participate with nor shall be excess over any
valid and collectable insurance or program of self-insurance carried or maintained by IRB. 
 10. TERMINATION 

10.1 Term. Unless earlier terminated as provided herein, this Agreement shall remain in full force and effect for the duration of the Term. 

10.2 Termination for Material Breach. Either party may terminate this Agreement upon 60 days prior written notice to the other party upon the material
breach by the other party of any of its obligations under this Agreement; provided, however, that such termination shall become effective only if the other party shall foil to remedy or cure the breach within such 60 day period. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 11 

 10.3 Termination by Humabs. Humabs may terminate this Agreement at it election upon 90
days’ prior written notice. 
 10.4 Effects of Termination.  

(a) Effect on License. Upon the expiration of the Term or earlier termination of this Agreement, the rights licensed under this Agreement shall
be treated as follows: 
 (i) Upon the expiration (but not earlier termination) of the Term of this Agreement. Licensee shall have a fully paid-up perpetual, irrevocable, royalty-free, transferable, worldwide, non-exclusive license under the Licensed IP of the same scope existing as of the date of such expiration
to develop use, make, have made, market, offer to sell, sell, have sold and import or export for sale Licensed Products: in the case of (partial) expiration because any patent claim has been annulled any payment made by Humabs to IRB shall not be
reimbursed any royalties calculated in accordance with this Agreement accrued until the date in which the decision annulling the patent claim has become definitive shall be paid by Humabs to IRB. 

(ii) Upon the termination of this Agreement by IRB pursuant to Section 10.2, the license granted to Licensee pursuant to Section 2.1
shall terminate, but, other than in the case that IRB has terminated this Agreement because the Licensee was in default with the payments hereunder and did not cure such default, Licensee shall receive a limited license to make, have made, use,
offer to sell, sell, have sold and import Licensed Products identified and developed by Licensee prior to the effective date of such termination (the “Limited License ‘); provided that Licensee shall continue to be obligated to pay IRB any
Royalties applicable to the sale of such Licensed Products as specified in Article 4. If after any such termination Licensee fails to pay any royalty amounts due under Article 4, IRB shall have the right to terminate the Limited License upon written
notice to Licensee. In the event that the termination of the Limited License or the non granting of the Limited License under this Section 10.6 (ii) affects any sublicense entered into by Humabs with Sublicensees, IRB shall grant a direct
license to such Sublicensees on the same terms and conditions as under the affected sublicense for the remaining term of the affected sublicense. The parties agree that this provision shall be regarded as a proper contract to the benefit of a third
party within the meaning of art. 112 (2) Code of Obligations and therefore the Sub licensees shall be entitled to directly rely on this provision to request IRB to enter into the direct license. 

(iii) Upon the termination of this Agreement by Humabs pursuant to Section 10.3, the license granted to the Licensee pursuant to
Section 2.1 shall terminate. In the event that this termination affects any sublicense entered into by Humabs with Sublicensees, IRB shall grant a direct license to such Sublicensees on the same terms and conditions as 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 12 

 under the affected sublicense for the remaining term of the affected sub license. The
parties agree that this provision shall be regarded as a proper contract to the benefit of a third party within the meaning of art. J 12 (2) Code of Obligations and therefore the Sublicensees shall be entitled to directly rely on this provision to
request IRB to enter into the direct license. 
 (b). Ongoing Obligations. 

Except where explicitly provided elsewhere herein, expiration or termination of this Agreement for any reason will not affect obligations,
including without Limitation the payment of any royalties or other sums which have accrued as of the date of termination or expiration, and rights and obligations which, from the context thereof, are intended to survive termination or
expiration of this Agreement. 
 Upon expiration or termination of this Agreement for any reason, each party shall immediately return to the
other party or destroy any Confidential Information disclosed by the other party, except for one copy which may be retained by its legal counsel in its confidential files for use only in monitoring its compliance with this Agreement. 

11. DISPUTE RESOLUTION 
 11.1
Disputes. Subject to Section 11.3, the parties shall attempt in good faith to resolve any and all claims, disputes or controversies arising under, out of, or in connection with the Agreement, including, without limitation, any
dispute relating to the validity or infringement of any Licensed 1P ( each, a “Dispute”), for a period of not less than [***] of either party’s written request that the parties commence such discussions. 

11.2 Arbitration. Any dispute, controversy or claim arising out of or in relation to this Agreement, including the validity, invalidity, breach or
termination thereof, shall be settled by arbitration in accordance with [***]. 
 11.3 Injunctive Relief. Notwithstanding anything to the contrary in
this Agreement, either party shall have the right, without waiving any right or remedy available to such party under this Agreement or otherwise, to seek and obtain from any court or arbitral tribunal of competent jurisdiction any interim or
provisional relief that is necessary or desirable to protect the rights or property of such party, pending the selection of the arbitrators or pending the arbitrators’ determination of any Dispute under Section 11.2 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 13 

 12. MISCELLANEOUS PROVISIONS 

Entire Agreement. This Agreement, the schedules and exhibits and other attachments hereto, if any, constitute and contain the entire understanding and
agreement of the parties respecting the subject matter or this Agreement and cancel and supersede any all prior negotiations, correspondence, understandings representations and agreements between the parties, whether oral or written, regarding such
subject matter. Humabs acknowledges that its wholly-owned subsidiary, Humabs BioMed, has entered into a separate license agreement wjth the IRB regarding intellectual property described therein, and Humabs consents to the terms of such agreement.

 Force Majeure. Nonperformance of a party (other than for the payment of money) shall be excused to the extent that performance is rendered
impossible by strike fire, earthquake, flood governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional
conduct or misconduct of the nonperforming party; provided however that the nonperforming party shall use commercially reasonable efforts to resume performance as soon as reasonably practicable. 

Further Actions. Each party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement. 
 Binding Effect. This Agreement and the rights granted herein hall be
binding upon and shall inure to the benefit of Licensee, IRB and their respective successors and permitted assigns. 
 Assignment. Except as otherwise
expressly provided under this Agreement Licensee shall not assign or other transfer this Agreement or any of its rights or obligations hereunder (whether voluntarily, by operation of law or otherwise), without the prior express written consent of
IRB, which consent shall not be unreasonably withheld. Notwithstanding the foregoing that Licensee may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or
substantially all of its business (if assigned to the transferee of such business), or in the event of its merger (if assigned to the merged entity), consolidation (if assigned to the consolidated entity), or other similar transaction. In the event
of a proposed transfer or sale of all or substantially all of its business, Licensee shall notify the IRB [***]. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment or transfer in
violation of this section shall be void. 
 No Implied Licenses. No rights of either party to any patents
know-how or technical information, or other intellectual property rights, other than as explicitly identified herein, are granted or deemed granted by this Agreement. 

No Third Party Rights. Except as expressly stated herein nothing in this Agreement shall confer any rights upon any person or entity other than the
parties and their respective successors and permitted assigns. 
 No Waiver. No waiver, modification or amendment of any provision of this Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer of such party. The failure of a party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 14 

 Independent Contractors. The parties are independent contractors under this Agreement.
Nothing contained in this Agreement is intended nor is to be construed so as to constitute Licensee or IRB as partners or joint venturers with respect to this Agreement. No party shall have any express or implied right or authority to
assume or create any obligations on behalf of or in the name of the other parties or to bind the other parties to any other contract, agreement or undertaking with any third party. 

Notices. All written notice required or permitted hereunder shall be in writing and shall be effective upon receipt if personally delivered or sent by
facsimile or internationally recognized delivery service to the address or fax number set forth below unless such address or fax number is changed by notice to the other party, as permitted hereunder. 

To IRB:             [***] 

To Licensee:     [***] 

Headings. The captions to the sections and articles in this Agreement are not a part of this Agreement and are included merely for convenience of
reference only and shall not affect its meaning or interpretation. 
 Severability. If any provision of this Agreement becomes or is declared by a
court of competent jurisdiction to be illegal unenforceable or void, this Agreement shall continue in full force and effect without said provision, so long as the Agreement, taking into account said voided provision(s}, continues to provide the
parties with the same practical economic benefits as the Agreement containing said voided provision(s} did on the effective date of this Agreement. If after taking into account said voided provision(s), the parties are unable to realize the
practical economic benefit contemplated by the parties the parties shall negotiate in good faith to amend this Agreement to reestablish the practical economic benefit provided the parties. 

Applicable Law. This Agreement shall be governed by and interpreted in accordance with the laws of Switzerland, without reference to its conflicts of
laws provisions. 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 15 

 Counterparts. This Agreement may be executed in counterparts, or facsimile versions, each of which
shall be deemed to be an original, and both of which together shall be deemed to be one and the same agreement. 
 [Signature page
follows] 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 16 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives. 
  

									
	THE INSTITUTE FOR RESEARCH	 		 	HUMABS HOLDING GMBH
					
	By:	 	 /s/ Giorgio Noseda
	 		 	By:	 	 /s/ William J. Rutter

	Name:	 	Prof. GIORGIO NOSEDA	 		 	Name:	 	William J. Rutter
	Title:	 	President of the IRB	 		 	Title:	 	CHAIRMAN

  

									
					
	By:	 	 /s/ Sandro Ru Coni
	 		 	By:	 	 /s/ Jakob Nuesch

	Name:	 	Prof. SANDRO RU CONI	 		 	Name:	 	Prof. Dr. Jakob Nuesch
	Title:	 	Member of the Foundation Council of the IRB	 		 	Title:	 	Member of Board

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 17 

 EXHIBIT A 

LIST OF PATENT APPLICATIONS AND PATENTS 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 
 18 

 HUMABS ACTIVE PORTFOLIO 

[***] 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 

 HUMABS ACTIVE PORTFOLIO 

[***] 

  

    /s/WJR    /s/SRC    /s/JN    /s/GN 

 

 HUMABS ACTIVE PORTFOLIO 

[***] 

  

    /s/WJR    /s/SRC    /s/JN    /s/GNEX-10.29

 Exhibit 10.29 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT TO LICENSE AGREEMENT 

Humabs Holding GmbH 
 And 

The Institute For Research in Biomedicine 

February 10, 2012 
 Whereas, Humabs Holding
GmbH (“Humabs”) and the Institute for Research in Biodmedicine (“IRB”) are parties to a license agreement dated as of December 16, 2011 (the “License Agreement”). 

Whereas, Humabs is in the business of commercializing novel antibodies and related IP licensed to Humabs by the IRB. 

Whereas, Humabs from time to time enters into sublicense agreements with third parties, as permitted by the License Agreement, and the parties have agreed to
make certain amendments to the License Agreement as set forth herein to accommodate requests of certain sublicensees. 
 Whereas, Humabs has, on or about
the date hereof, entered into a sublicense agreement with MedImmune; references herein to “sublicensee” shall apply only to Medimmune unless and until the parties agree in writing to add other sublicensees who will also be included
hereunder. 
 Therefore, the parties agree as follows: 

Section 2.2 of the License Agreement shall be amended by adding the following sentence at the end of such section: “Copies of sublicense
agreements hereunder may be redacted where required by the sublicensee to remove financial and other information if and to the extent required by the sublicensee.” “IRB acknowledges that the terms of such sub-license agreement are confidential and shall be treated as confidential information of Humabs in accordance with clause 5.4. IRB shall not disclose such sub-license
agreement or any terms thereof to any person without the prior express written consent of such sub-licensee, which consent may be withheld by such sub-licensee in its
sole discretion. IRB shall limit internal disclosure of such sub-license agreement only to persons with a need to know and who are bound by obligations of confidentiality with respect thereto equivalent to
those set forth in the sub-license agreement.” 

  
 Page 1 of 3 

 Section 2.3 of the License Agreement shall be amended by striking the prior provisions thereof and
substituting the following in its place: “The IRB retains the right to practice the Licensed IP solely for internal research purposes. (and not for commercial exploitation); such Licensed IP may be used for teaching or education only
to the extent it is has been published in a patent application or otherwise properly publicly disclosed, and for clarity in no event will any such IP, or related knowhow or antibodies be used for teaching or education if such IP, knowhow
or antibodies is confidential under the License Agreement or Research Agreement between IRB and Humabs (including without limitation Research Inventions, Knowhow, Research Records and Data as defined therein) or if such IP, knowhow or antibodies
have been exclusively licensed to a sublicensee under terms which prohibit its use for such purposes. Such retained rights shall be non-exclusive, non-transferable,
and non-sublicensable. Notwithstanding the foregoing, the IRB may [***]. The IRB may not [***]. For the avoidance of doubt the parties acknowledge that any practicing of the Licensed IP by IRB with the
purpose to [***]. Anything herein to the contrary notwithstanding, IRB may not [***].” 
 Section 5.3(b) of the License Agreement shall be amended
by striking the reference to “Sublicensees” therefrom. 
 Section 5.7 of the License Agreement shall be amended by adding the following
sentence at the end of such section: “The foregoing notwithstanding, any publication which contains information related to research projects undertaken in connection with a research agreement between Humabs and a third party shall not be
published without the approval of such third party in such third party’s sole discretion.” 
 Section 7.1 of the License Agreement shall
be amended by adding the following sentence at the end of such section: “Anything herein to the contrary notwithstanding, IRB may not transfer to any third party any antibodies generated by IRB pursuant to research undertaken for
Humabs or a third party or any related know-how, materials or results.” 

  
 Page 2 of 3 

					
	
	 Executed as of the date first above written.

		
		 	 Humabs GmbH

			
		 	By:	 	 /s/ Jakob Nūesch

		 	 Title:
	 	 Member of the Board

		
		 	 Institute for Research in Biomedicine

			
		 	By:	 	 /s/ Paolo Agustoni

		 	 Title:
	 	 Member of IRB Foundation Council

			
		 	By:	 	 /s/ Mariagrazia Uguccioni

		 	 Title:
	 	 IRB Vice-Director

  
 Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]